Clinical trials: Male Osteoporosis
Hypogonadism, Paraplegia
Efficacy of Nebido on Bone Mineral Density (BMD) in Hypogonadal Paraplegic Patients With Confirmed Osteoporosis
Both conditions hypogonadism and immobilisation (paraplegia) may contribute or lead to decreased bone mineral density resp osteoporosis.
- Conditions
- Hypogonadism, Paraplegia, Bone Density, Osteoporosis
- Trial name
- NCT00838838
- Testing
- Testosterone Undeconate (Nebido-R, BAY86-5037)
- Where
- Germany
- Volunteers
- 26 people
- Sponsor
- Bayer
Prostate Cancer, Osteoporosis
Prevalence of Osteoporosis in Korean Prostate Cancer Patients Who is Receiving LHRH Agonist and/or Anti-androgen Agent
Prevalence rate of osteoporosis and it's actual management condition in Prostate cancer patients who takes LHRH antagonist and anti androgen
- Trial name
- NCT01025479
- Where
- 18 sites in South Korea
- Volunteers
- 829 people
- Sponsor
- AstraZeneca
Prostate Cancer
The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
The purpose of this study is to compare the effect of an investigational drug used intravenously and placebo administered every three months for one year, on bone loss associated with initial androgen deprivation) in men with…
- Trial name
- NCT00063609
- Testing
- zoledronic acid
- Where
- 44 sites in United States
- Volunteers
- 200 people
- Sponsor
- Novartis Pharmaceuticals
Osteoporosis
Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China
The primary objective of this study is to evaluate the efficacy of Prolia on lumbar spine BMD at 12 months.
- Trial name
- NCT06332014
- Testing
- Prolia
- Where
- 16 sites in China
- Volunteers
- 102 people
- Sponsor
- Amgen
Male Osteoporosis
The Effect Of Oral Ibandronate In Male Osteoporosis
Male osteoporosis is a common and important clinical problem, associated with significant morbidity, mortality and societal expense. Approximately 10% of men =65 years of age are osteoporotic.
- Trial name
- STRONG (NCT00397839)
- Testing
- Ibandronate
- Where
- 41 sites in United States
- Volunteers
- 135 people
- Sponsor
- Hoffmann-La Roche
Low Bone Mass, Low Bone Mineral Density
Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis
The purpose of this study is to assess how effective and safe denosumab is in a population of males with low bone mass at risk of fracture.
- Conditions
- Low Bone Mass, Low Bone Mineral Density, Males With Osteoporosis, Osteopenia
- Trial name
- NCT00980174
- Testing
- 60 mg denosumab
- Volunteers
- 242 people
- Sponsor
- Amgen
Osteoporosis, Osteoporosis, Age-Related
Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM)
A 12-month study to measure the efficacy and safety of abaloparatide in men with osteoporosis.
- Conditions
- Osteoporosis, Osteoporosis, Age-Related, Osteoporosis Localized to Spine, Age Related Osteoporosis
- Trial name
- NCT03512262
- Testing
- Abaloparatide
- Where
- 34 sites in United States, Italy and 1 more
- Volunteers
- 228 people
- Sponsor
- Radius Health, Inc.
Prostate Cancer, Osteoporosis
Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy
Androgen deprivation therapy (ADT) treatment for prostate cancer decreases the natural hormone called testosterone. This type of therapy is very effective for the treatment of prostate cancer.
- Conditions
- Prostate Cancer, Osteoporosis, Fractures
- Trial name
- NCT00129142
- Testing
- Toremifene Citrate
- Where
- 155 sites in United States, Mexico
- Volunteers
- 1,200 people
- Sponsor
- GTx
Postmenopausal Osteoporosis
Phase 1 Study to Compare CMAB807 Injection to Prolia® in Healthy Volunteers
CMAB807 is a human monoclonal antibody targeting the key bone resorption mediator RANKL. The drug is administered via subcutaneous injection once six months and is approved for various indications, including the treatment of…
- Trial name
- NCT03925051
- Testing
- Prolia®, CMAB807
- Where
- China
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Shanghai Biomabs Pharmaceutical Co., Ltd.
Amyotrophic Lateral Sclerosis (ALS), Angina, Stable
Quest to Analyze One Thousand Humans Meditating
This study will be focused on assessing the molecular, physiological, and emotional correlates of an intensive meditation experience in the context of a retreat setting in a large 2000 plus-person cohort comprised of healthy and…
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma
- Trial name
- QUANTUM (NCT06583395)
- Testing
- Advanced multi-component meditation practice
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Tobias Moeller-Bertram
Prostate Cancer
The Use of Zoledronic Acid in Men on Androgen Deprivation Therapy for Prostate Cancer With Preexisting Osteoporosis
This study is being conducted to evaluate the effect of an investigational drug on bone loss in men with prostate cancer who are receiving Androgen Deprivation Therapy (ADT).
- Trial name
- NCT00171639
- Testing
- zoledronic acid
- Where
- 7 sites in United States
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Osteoporosis, Postmenopausal
A Clinical Trial to Evaluate the Safety and Pharmacokinetic
A phase 1 clinical trail to evaluate the safety and pharmacokinetic characteristic after administration of fixed-dose combination or loose combination of HUG186 in healthy adult male or menopausal female volunteers
- Trial name
- NCT03475719
- Testing
- HUG186-B and HUG186-D, HUG186
- Where
- South Korea
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Huons Co., Ltd.
Osteoporosis
A Study To Investigate The Metabolism And Excretion Of 14C SB-751689 Given To Healthy Males And Postmenopausal Women
This study will examine the biological fate of radioactive SB-751689 administered to healthy males and healthy postmenopausal women. Subjects will receive a single oral dose of radioactive SB-751689.
- Trial name
- NCT00499928
- Testing
- SB-751689
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Osteoporosis, Prostate Cancer
Awareness to Osteopenia's Treatment by Bisphosphonate in Male Suffering From Prostate Cancer
Patients with prostate cancer treated in outpatient clinics will be recruited by their urologist physician. Primary Objective: To evaluate the compliance in male patients with prostate cancer treated with Bisphosphonate and that…
- Trial name
- InoPro (NCT00816452)
- Where
- Israel
- Volunteers
- 180 people
- Sponsor
- Sanofi
Osteoporosis
Evaluating the Pharmacokinetic Characteristics of AD-102 in Healthy Volunteers
The purpose of this study is to evaluate the pharmacokinetic characteristics of AD-102 in healthy male subjects
- Trial name
- NCT03824171
- Testing
- Raloxifene 60mg/Cholecalciferol 800IU, AD-102
- Where
- South Korea
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Osteoporosis
Study of Multiple Oral Doses of Odanacatib (MK0822) in Healthy Adults (0822-002)
This study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of once-daily multiple-dose administration of odanacatib (MK0822).
- Trial name
- NCT00769418
- Testing
- odanacatib
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Osteoporosis
Safety and Tolerability of Odanacatib (0822-059)
This study will test the weighted average inhibition of u-NTx/Cre (aminoterminal crosslinked telopeptide of Type 1 collagen) and AUC (0-168 hours) of Odanacatib
- Trial name
- NCT01068262
- Testing
- Odanacatib
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of Single and Multiple-Doses of ATF936 and AXT914 Administered Orally in Healthy Subjects.
This is a first-in-human study and is designed to evaluate the safety, tolerability, pharmacodynamic and pharmacokinetic effects of a single and multiple-doses of ATF936 and AXT914 administered orally in healthy subjects.
- Trial name
- NCT00417261
- Testing
- ATF936, AXT914
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Novartis
Osteoporosis
HDDO-1614 Bio Equivalence Study
A randomized, open-label, single-dose, crossover study
- Trial name
- NCT03382314
- Testing
- HDDO-1614, Bazedoxifene / Cholecalciferol
- Where
- South Korea
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Hyundai Pharmaceutical Co., LTD.
Osteoporosis
Assess Bioequivalence of One 150 mg Risedronate Tablet Versus Two 75 mg Risedronate Tablets in Healthy Subjects
This study is a randomized, open-label, crossover study to assess the bioequivalence of 1 risedronate 150 mg tablet versus 2 risedronate 75 mg tablets administered as a single oral dose.
- Trial name
- NCT00699777
- Testing
- Risedronate
- Where
- 4 sites in United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Warner Chilcott